Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2024-03-29 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
前沿生物董事会审计委员会对2023年度会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the accounting firm for the 2023 fiscal year audit. It details the audit firm's qualifications, the audit committee's oversight activities, and the audit process for the 2023 annual financial statements. It does not contain the full annual report or financial statements but focuses on the audit supervision and evaluation of the audit firm's performance. This matches the description of an Audit Report / Information filing, which includes standalone audit reports and related supervisory information. The document length is 1737 characters, which is sufficient for a detailed audit supervision report but not a full annual report. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2023
2024-03-29 Chinese
前沿生物药业（南京）股份有限公司股东大会议事规则
Governance Information Classification · 95% confidence The document is titled as "股东大会议事规则" which translates to "Rules of Procedure for the Shareholders' General Meeting" of a company. It extensively details the governance, procedures, rights, and responsibilities related to the shareholders' meetings, including the convening, proposal submission, voting, and resolution processes. It does not contain financial statements, audit opinions, or earnings data. Instead, it focuses on the internal governance rules and operational procedures of the shareholders' meetings, which aligns with governance information. Therefore, the document fits best under the category of Governance Information (CGR). The document length and content confirm it is a full governance report, not a brief announcement or notice.
2024-03-29 Chinese
前沿生物对独立董事2023年度独立性自查情况的专项报告
Governance Information Classification · 95% confidence The document is a special report from the Board of Directors regarding the independence self-assessment of independent directors for the year 2023. It references regulatory requirements about independent directors and confirms their compliance and independence. This is a governance-related disclosure about board members' independence, not a full annual report, audit report, or financial statement. It is not a meeting presentation, voting result, or management change announcement. The content fits best under Governance Information (CGR) as it details governance practices and board structure compliance.
2024-03-29 Chinese
前沿生物关于召开2023年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2023 Annual General Meeting (AGM) of the company, including details about the meeting date, voting procedures, agenda items, and proxy forms. It does not contain the actual annual report or financial statements but rather the announcement and logistical information for the AGM. The document length is 4454 characters, which is relatively short and consistent with an announcement rather than a full report. The document explicitly states it is a notice for the 2023 annual shareholders meeting and lists the agenda items to be voted on, including the 2023 annual report and financial statements, but does not include these reports themselves. Therefore, this document fits the category of AGM Information (AGM-R).
2024-03-29 Chinese
中信证券股份有限公司关于前沿生物药业（南京）股份有限公司2023年度募集资金存放与使用情况的专项核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2023 annual special audit opinion on the deposit and use of raised funds by Qianyan Biopharmaceutical (Nanjing) Co., Ltd. It includes extensive financial data on fundraising amounts, usage, balances, investment projects, cash management, and compliance with regulatory requirements. The document references regulatory guidelines and audit reports, and it is focused on the management and use of capital raised by the company. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2024-03-29 Chinese
中审众环会计师事务所（特殊普通合伙）关于前沿生物药业（南京）股份有限公司2023年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled "内部控制审计报告" (Internal Control Audit Report) issued by Zhongshenzhonghuan Certified Public Accountants LLP, containing audit opinion on the effectiveness of the company’s financial reporting internal control as of December 31, 2023. It clearly is a standalone audit report (auditor’s opinion and findings) rather than an Annual Report or announcement. Therefore, it matches the Audit Report / Information category. FY 2023
2024-03-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.